List of Fetroja drug patents

Fetroja is owned by Shionogi Inc.

Fetroja contains Cefiderocol Sulfate Tosylate.

Fetroja has a total of 3 drug patents out of which 0 drug patents have expired.

Fetroja was authorised for market use on 14 November, 2019.

Fetroja is available in powder;intravenous dosage forms.

Fetroja can be used as method of treating bacterial infections.

Drug patent challenges can be filed against Fetroja from November, 2028.

The generics of Fetroja are possible to be released after 03 September, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2033

(10 years from now)

US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
New Indication (I) Sep 25, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: November, 2028

Market Authorisation Date: 14 November, 2019

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in